Piramal Pharma (NSE:PPLPHARMA) LT-Debt-to-Total-Asset: 0.25 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:PPLPHARMA Piramal Pharma Ltd NSE:PPLPHARMA
51 GF Score
Price ₹174.79
GF Value ₹175.22
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Piramal Pharma LT-Debt-to-Total-Asset?

Piramal Pharma NSE:PPLPHARMA +1.82% 51 LT-Debt-to-Total-Asset is 0.25 as of Mar. 2026. GuruFocus rates NSE:PPLPHARMA with a GF Score™ of 51/100 and a GF Value™ of ₹175.22 (Fairly Valued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Piramal Pharma's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.25.

Piramal Pharma's long-term debt to total assets ratio increased from Mar. 2025 (0.21) to Mar. 2026 (0.25). It may suggest that Piramal Pharma is progressively becoming more dependent on debt to grow their business.

Piramal Pharma  (NSE:PPLPHARMA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Piramal Pharma LT-Debt-to-Total-Asset Related Terms

Piramal Pharma LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Piramal Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Piramal Pharma LT-Debt-to-Total-Asset Chart

Piramal Pharma Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.21 0.24 0.17 0.21 0.25

Piramal Pharma Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.00 0.21 0.00 0.25
NSE:PPLPHARMA
51GF Score
Piramal Pharma Ltd NSE:PPLPHARMA
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Piramal Pharma LT-Debt-to-Total-Asset Calculation

Piramal Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (A: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2026 )/Total Assets (A: Mar. 2026 )
=44354/179650.4
=0.25

Piramal Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=44354/179650.4
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.25 mean?
Piramal Pharma (NSE:PPLPHARMA) has a LT-Debt-to-Total-Asset of 0.25 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Piramal Pharma and its competitors.
Is Piramal Pharma's LT-Debt-to-Total-Asset too high?
Piramal Pharma's current LT-Debt-to-Total-Asset is 0.25. Overall, Piramal Pharma has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's LT-Debt-to-Total-Asset compare to ZTS and UTHR?
Piramal Pharma's LT-Debt-to-Total-Asset of 0.25 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Piramal Pharma and its competitors. Piramal Pharma's current LT-Debt-to-Total-Asset is 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹175.22, compared to a current price of ₹174.79 — trading 0.2% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.25. Piramal Pharma's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current LT-Debt-to-Total-Asset is 0.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Piramal Pharma stock appears to be undervalued. The current stock price of ₹174.79 is trading 0.2% below its estimated GF Value™ of ₹175.22. GuruFocus considers Piramal Pharma to be Fairly Valued.

Key valuation signals for NSE:PPLPHARMA:

  • LT-Debt-to-Total-Asset: 0.25
  • GF Value™: ₹175.22 vs. price of ₹174.79 (0.2% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Piramal Pharma Business Description

Other Exchanges 543635:India
Address Kamani Junction, LBS Marg, Ground Floor, Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kurla (West), Mumbai, MH, IND, 400070
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
51GF Score

Get the complete analysis for NSE:PPLPHARMA

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹174.79
Price
₹175.22
GF Value